Funding Opportunities

Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.

 

For funding opportunities related to global health, please see the Vanderbilt Institute for Global Health announcements found here.

Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed), expires: 07/29/2023

Application Due Date(s): July 28, 2021; July 28, 2022; July 28, 2023, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from research institutions in low- to middle-income countries (LMIC) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The ultimate goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in low to middle-income countries.

https://grants.nih.gov/grants/guide/pa-files/PAR-21-037.html

HIV Prevention Trials Network (HPTN) Scholars Program (Domestic and International), due annually January

Application due:

  • Initial proposal drafts for Domestic Scholars are due 5 January 2018 and full applications are due 19 January 2018
  • Initial proposal drafts for International Scholars are due 29 January 2018 and full applications are due 12 February 2018

The HIV Prevention Trials Network (HPTN) is proud to offer two scholarship programs for early-career investigators funded through a supplement from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute on Drug Abuse (NIDA). The HPTN Scholars Program now includes two components: a domestic (U.S.) program and an international program. Both programs seek to increase opportunities for scientists from groups under-represented in HIV prevention research. In the domestic program, successful applicants will be Investigators who have received their terminal degree (MD, Phd, etc). For the international version, current MD, PhD, and MBChB students may apply, along with individuals having already graduated with their terminal degree. In both programs, applicants should desire to work with a mentor scientist in the Network to complete a research project based upon an existing HPTN research study.

https://hptn.org/research/scholars

Vanderbilt Trans-Institutional Programs (Internal Opportunity), due annually 10/30

https://www.vanderbilt.edu/provost/occi/tips.php

Vanderbilt Initiative Awards (ViA):

  • Small-scale or new initiatives that showcase potential to become a major hub of activity - center or institute - that will advance the core missions of Vanderbilt
  • Provide seed funding up to $100,000 per year.
  • Provide faculty the opportunity to pursue innovative ideas for discovery and learning with colleagues from diverse disciplines.
  • Must include collaborators from multiple schools and colleges.* 

Vanderbilt Reinvestment Awards (VRA):

  • Awarded to existing centers and institutes that facilitate learning collaborations across campus.
  • Assist collaborations taking a critical next step in order to ensure continued success.
  • Funding varies on a case-by-case basis.
  • Must secure partnerships with respective deans as part of the full-proposal submission process.

Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 and R21), expires: 01/14/2022

R01 Application Due Date(s): January 14, 2020, January 14, 2021, and January 14, 2022 by 5:00 PM local time of applicant organization.

R21 Application Due Date(s): January 14, 2020; January 14, 2021, by 5:00 PM local time of applicant organization

This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.

R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-307.html

R21: https://grants.nih.gov/grants/guide/pa-files/PAR-18-923.html